List of Orladeyo drug patents

Orladeyo is owned by Biocryst.

Orladeyo contains Berotralstat Hydrochloride.

Orladeyo has a total of 6 drug patents out of which 0 drug patents have expired.

Orladeyo was authorised for market use on 03 December, 2020.

Orladeyo is available in capsule;oral dosage forms.

Orladeyo can be used as prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older, prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older.

Drug patent challenges can be filed against Orladeyo from December, 2024.

The generics of Orladeyo are possible to be released after 01 November, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(12 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic